James C Fleet

Prof. James C Fleet

orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2014 in Immunity
Verified
Journal Article
Closed access
MVMadhukumar Venkatesh
Madhukumar Venkatesh
SMSubhajit Mukherjee
Subhajit Mukherjee
HWHongwei Wang
Hongwei Wang
HLHao Li
Hao Li
KSKatherine Sun
Katherine Sun
SMSRIDHAR MANI
SRIDHAR MANI

14 December 2011 in Biochemical Journal
Verified
Journal Article
Closed access
PDF file
JFJames C Fleet
James C Fleet
MDMarsha Desmet
Marsha Desmet
RJRobert Johnson
Robert Johnson
YLYan Li
Yan Li
The population-based association between low vitamin D status and increased cancer risk can be inconsistent, but it is now generally accepted. These relationships link low serum 25OHD (25-hydroxyvitamin D) levels to cancer, whereas cell-based studies show that the metabolite 1,25(OH)2D (1,25-dihydroxyvitamin D) is a biologically active metabolite that works through vitamin D receptor to regulate gene transcription. In the present review we discuss the literature relevant to the molecular events that may account for the beneficial impact of vitamin D on cancer prevention or treatment. These data show that although vitamin D-induced growth arrest and apoptosis of tumour cells or their non-neoplastic progenitors are plausible mechanisms, other chemoprotective mechanisms are also worthy of consideration. These alternative mechanisms include enhancing DNA repair, antioxidant protection and immunomodulation. In addition, other cell targets, such as the stromal cells, endothelial cells and cells of the immune system, may be regulated by 1,25(OH)2D and contribute to vitamin D-mediated cancer prevention.

17 October 2011 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
EFEmily G. Farrow
Emily G. Farrow
XYXijie Yu
Xijie Yu
LSLelia J. Summers
Lelia J. Summers
SDSiobhan I. Davis
Siobhan I. Davis
JFJames C Fleet
James C Fleet
KWKenneth E. White
Kenneth E. White
Autosomal dominant hypophosphatemic rickets (ADHR) is unique among the disorders involving Fibroblast growth factor 23 (FGF23) because individuals with R176Q/W and R179Q/W mutations in the FGF23 176 RXXR 179 /S 180 proteolytic cleavage motif can cycle from unaffected status to delayed onset of disease. This onset may occur in physiological states associated with iron deficiency, including puberty and pregnancy. To test the role of iron status in development of the ADHR phenotype, WT and R176Q-Fgf23 knock-in (ADHR) mice were placed on control or low-iron diets. Both the WT and ADHR mice receiving low-iron diet had significantly elevated bone Fgf23 mRNA. WT mice on a low-iron diet maintained normal serum intact Fgf23 and phosphate metabolism, with elevated serum C-terminal Fgf23 fragments. In contrast, the ADHR mice on the low-iron diet had elevated intact and C-terminal Fgf23 with hypophosphatemic osteomalacia. We used in vitro iron chelation to isolate the effects of iron deficiency on Fgf23 expression. We found that iron chelation in vitro resulted in a significant increase in Fgf23 mRNA that was dependent upon Mapk. Thus, unlike other syndromes of elevated FGF23, our findings support the concept that late-onset ADHR is the product of gene–environment interactions whereby the combined presence of an Fgf23-stabilizing mutation and iron deficiency can lead to ADHR.

1 September 2017 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
JFJames C Fleet
James C Fleet

1 August 2010 in Critical Reviews in Clinical Laboratory Sciences
Verified
Journal Article
Closed access
PDF file
JFJames C Fleet
James C Fleet
RSRyan D. Schoch
Ryan D. Schoch
Optimal intestinal calcium (Ca) absorption is necessary for the protection of bone and the prevention of osteoporosis. Ca absorption can be represented as the sum of a saturable pathway and a non-saturable pathway that is primarily dependent upon luminal Ca concentration. While models have been proposed to describe these transport components, significant gaps still exist in our understanding of these processes. Habitual low intake of Ca up-regulates the saturable transport pathway, a process mediated by increased renal production of 1,25 dihydroxyvitamin D (1,25(OH)2D). Consistent with this, low vitamin D status as well as deletion/mutation of the vitamin D receptor (VDR) or 25 hydroxyvitamin D-1α hydroxylase (CYP27B1) genes limit Ca absorption by reducing the saturable pathway. There is some evidence that non-saturable Ca absorption in the ileum is also regulated by vitamin D status, but the mechanism is unclear. Treatment with a number of hormones can regulate Ca absorption in vivo (e.g. parathyroid hormone (PTH), thyroid hormone, growth hormone (GH)/insulin-like growth factor I (IGF-1), estrogen, testosterone). However, some of these actions are indirect (i.e. mediated through the regulation of vitamin D metabolism or signaling), whereas only a few (e.g. estrogen, IGF-1) have been shown to persist in the absence of vitamin D signaling.

1 November 2010 in Developmental Cell
Verified
Journal Article
Closed access
MVMichael P. Verzi
Michael P. Verzi
HSHyunjin Shin
Hyunjin Shin
HHH. Hansen He
H. Hansen He
RSRita Sulahian
Rita Sulahian
CMClifford A. Meyer
Clifford A. Meyer
RSRamesh A. Shivdasani
Ramesh A. Shivdasani